



Resource: ART Drug-Drug Interactions

August 2024

Table 46: COVID-19 Therapeutics (also see drug package inserts and emergency use authorizations [FDA(c) 2024; FDA(b) 2023])		
→ Molnupiravir, nirmatrelvir/ritonavir (RTV), monoclonal antibodies		
Class or Drug	Mechanism of Action	Clinical Comments
<ul style="list-style-type: none"> All NRTIs Doravirine (DOR) Etravirine (ETR) Rilpivirine (RPV) Cabotegravir (CAB) Dolutegravir (DTG) Raltegravir (RAL) 	No clinically significant interactions expected.	No dose adjustments are necessary.
<ul style="list-style-type: none"> Efavirenz (EFV) Nevirapine (NVP) Bictegravir (BIC) Fostemsavir (FTR) Maraviroc (MRV) 	<ul style="list-style-type: none"> Molnupiravir and monoclonal antibodies do not affect CYP450, P-gP, or other drug metabolism transporters. Nirmatrelvir/RTV: Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other medications. 	<ul style="list-style-type: none"> Molnupiravir, monoclonal antibodies: Drug interactions are unlikely. Nirmatrelvir/RTV: Drug interactions are unlikely; ARV levels may increase.
All PIs and boosted PIs	<ul style="list-style-type: none"> Molnupiravir and monoclonal antibodies do not affect CYP450, P-gP, or other drug metabolism transporters. Nirmatrelvir/RTV: Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other PIs. 	<ul style="list-style-type: none"> Molnupiravir, monoclonal antibodies: Drug interactions are unlikely. Nirmatrelvir/RTV: Patients on RTV- or COBI-containing regimens should continue treatment for COVID-19 and HIV as indicated without adjustment. Monitor for increased PI-related adverse effects.
Elvitegravir (EVG), boosted	<ul style="list-style-type: none"> Molnupiravir and monoclonal antibodies do not affect CYP450, P-gP, or other drug metabolism transporters. Nirmatrelvir/RTV: Inhibition of CYP3A4, P-gP, and other transporters may increase plasma concentrations of other medications. 	<ul style="list-style-type: none"> Molnupiravir, monoclonal antibodies: Drug interactions are unlikely. Nirmatrelvir/RTV: Patients on RTV- or COBI-containing regimens should continue treatment as indicated. Monitor for increased EVG-related adverse effects.
Abbreviations: ARV, antiretroviral; COBI, cobicistat; CYP, cytochrome P450; NRTI, nucleoside reverse transcriptase inhibitor; P-gP, P-glycoprotein.		

References

FDA(b). Paxlovid (nirmatrelvir tablets; ritonavir tablets), co-packaged for oral use. 2023 May.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf [accessed 2022 Jun 30]

FDA(c). Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. 2024 Jun. <https://www.fda.gov/media/155054/download> [accessed 2022 Jun 30]